580 related articles for article (PubMed ID: 28687830)
21. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
22. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma.
Chen Y; Wu X; Bu S; He C; Wang W; Liu J; Guo W; Tan B; Wang Y; Wang J
Cancer Sci; 2012 Nov; 103(11):1979-84. PubMed ID: 22845557
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.
Dipetrillo T; Suntharalingam M; Ng T; Fontaine J; Horiba N; Oldenburg N; Perez K; Birnbaum A; Battafarano R; Burrows W; Safran H
Am J Clin Oncol; 2012 Feb; 35(1):64-7. PubMed ID: 21297434
[TBL] [Abstract][Full Text] [Related]
24. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
[TBL] [Abstract][Full Text] [Related]
25. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang H; Tang H; Fang Y; Tan L; Yin J; Shen Y; Zeng Z; Zhu J; Hou Y; Du M; Jiao J; Jiang H; Gong L; Li Z; Liu J; Xie D; Li W; Lian C; Zhao Q; Chen C; Zheng B; Liao Y; Li K; Li H; Wu H; Dai L; Chen KN
JAMA Surg; 2021 May; 156(5):444-451. PubMed ID: 33729467
[TBL] [Abstract][Full Text] [Related]
26. A randomized phase 3 trial comparing paclitaxel plus 5-fluorouracil versus cisplatin plus 5-fluorouracil in Chemoradiotherapy for locally advanced esophageal carcinoma-the ESO-shanghai 1 trial protocol.
Chen Y; Zhu Z; Zhao W; Li L; Ye J; Wu C; Tang H; Lin Q; Li J; Xia Y; Li Y; Zhou J; Zhao K
Radiat Oncol; 2018 Feb; 13(1):33. PubMed ID: 29482649
[TBL] [Abstract][Full Text] [Related]
27. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
Spigel DR; Greco FA; Meluch AA; Lane CM; Farley C; Gray JR; Clark BL; Burris HA; Hainsworth JD
J Clin Oncol; 2010 May; 28(13):2213-9. PubMed ID: 20351330
[TBL] [Abstract][Full Text] [Related]
29. Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer.
Crosby T; Hurt CN; Falk S; Gollins S; Staffurth J; Ray R; Bridgewater JA; Geh JI; Cunningham D; Blazeby J; Roy R; Maughan T; Griffiths G; Mukherjee S
Br J Cancer; 2017 Mar; 116(6):709-716. PubMed ID: 28196063
[TBL] [Abstract][Full Text] [Related]
30. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.
Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K
J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723
[TBL] [Abstract][Full Text] [Related]
31. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2).
Higuchi K; Komori S; Tanabe S; Katada C; Azuma M; Ishiyama H; Sasaki T; Ishido K; Katada N; Hayakawa K; Koizumi W;
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):872-9. PubMed ID: 24867539
[TBL] [Abstract][Full Text] [Related]
32. Phase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.
DiSilvestro PA; Ali S; Craighead PS; Lucci JA; Lee YC; Cohn DE; Spirtos NM; Tewari KS; Muller C; Gajewski WH; Steinhoff MM; Monk BJ
J Clin Oncol; 2014 Feb; 32(5):458-64. PubMed ID: 24395863
[TBL] [Abstract][Full Text] [Related]
33. Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial.
Chen Y; Ye J; Zhu Z; Zhao W; Zhou J; Wu C; Tang H; Fan M; Li L; Lin Q; Xia Y; Li Y; Li J; Jia H; Lu S; Zhang Z; Zhao K
J Clin Oncol; 2019 Jul; 37(20):1695-1703. PubMed ID: 30920880
[TBL] [Abstract][Full Text] [Related]
34. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
Curran WJ; Paulus R; Langer CJ; Komaki R; Lee JS; Hauser S; Movsas B; Wasserman T; Rosenthal SA; Gore E; Machtay M; Sause W; Cox JD
J Natl Cancer Inst; 2011 Oct; 103(19):1452-60. PubMed ID: 21903745
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
Bradley JD; Hu C; Komaki RR; Masters GA; Blumenschein GR; Schild SE; Bogart JA; Forster KM; Magliocco AM; Kavadi VS; Narayan S; Iyengar P; Robinson CG; Wynn RB; Koprowski CD; Olson MR; Meng J; Paulus R; Curran WJ; Choy H
J Clin Oncol; 2020 Mar; 38(7):706-714. PubMed ID: 31841363
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of concurrent chemoradiotherapy combined with a weekly paclitaxel and 5-fluorouracil regimen to treat patients with advanced oesophageal carcinoma.
Xia Y; Li YH; Chen Y; Zhang JH; Liu Q; Deng JY; Ai TS; Zhu HT; Fan JH; Badakhshi H; Zhao KL
Radiat Oncol; 2017 Mar; 12(1):47. PubMed ID: 28270162
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of concurrent chemoradiotherapy with elective nodal irradiation for inoperable esophageal cancer.
Jing Z; Chen T; Zhang X; Wu S
Cancer Sci; 2017 Sep; 108(9):1828-1833. PubMed ID: 28665042
[TBL] [Abstract][Full Text] [Related]
38. nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial.
Oppelt P; Ley J; Daly M; Rich J; Paniello R; Jackson RS; Pipkorn P; Liu J; Gay H; Palka K; Neupane P; Powell S; Spanos WC; Gitau M; Zevallos J; Thorstad W; Adkins D
Med Oncol; 2021 Mar; 38(4):35. PubMed ID: 33683482
[TBL] [Abstract][Full Text] [Related]
39. Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: a prospective, multicenter phase II trail.
Meng X; Wang J; Sun X; Wang L; Ye M; Feng P; Zhu G; Lu Y; Han C; Zhu S; Liao Z; Yu J
Radiother Oncol; 2013 Nov; 109(2):275-80. PubMed ID: 24128808
[TBL] [Abstract][Full Text] [Related]
40. The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Weidhaas JB; Harris J; Schaue D; Chen AM; Chin R; Axelrod R; El-Naggar AK; Singh AK; Galloway TJ; Raben D; Wang D; Matthiesen C; Avizonis VN; Manon RR; Yumen O; Nguyen-Tan PF; Trotti A; Skinner H; Zhang Q; Ferris RL; Sidransky D; Chung CH
JAMA Oncol; 2017 Apr; 3(4):483-491. PubMed ID: 28006059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
